secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001104659-26-043425
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics appoints Matthew Lang as COO and General Counsel
-----------------------------------------------------------------------

- Lang effective April 15, 2026; salary $560,000/yr with 40% target bonus.
- Equity grant: options for 223,776 ordinary shares (74,592 ADSs), time-based RSUs for 184,614 ordinary shares, and PSUs for 46,155 ordinary shares at target.
- Former Chief Legal Officer at Metsera, where he helped guide the up to $10B Pfizer acquisition; also held exec roles at Lyell, Myovant, and Gilead.
- Company advancing aleniglipron into Phase 3 for obesity; Lang to support operational foundation and strategic priorities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926043425/0001104659-26-043425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926043425/tm2611763d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-043425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer